Printer Friendly

INSTITUTE FOR LABORATORY MEDICINE REPORTS FIRST QUARTER RESULTS

       INSTITUTE FOR LABORATORY MEDICINE REPORTS FIRST QUARTER RESULTS
    MIAMI, Nov. 19 /PRNewswire/ -- Institute for Laboratory Medicine, Inc. (NASDAQ: LABS), today reported results for the quarter ended Sept. 30, 1991.
                 INSTITUTE FOR LABORATORY MEDICINE, INC.
                              (Unaudited)
     Period ended                                 Three months
     Sept. 30;                                1991           1990
    Net Revenues                           $2,320,504      $2,282,906
    Net income (loss)                       ($334,190)       $206,244
    Net income (loss) per share                ($0.06)          $0.09
    Weighted average number
     of common shares outstanding           5,623,915       2,256,324
    -0-          11/19/91
    /CONTACT:  Richard A. Bendis, chairman of Institute for Laboratory Medicine, 305-653-1700/
    (LABS) CO:  Institute for Laboratory Medicine, Inc. ST:  Florida IN:  MTC SU:  ERN FC-SM -- NY082 -- 5117 11/19/91 16:50 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 19, 1991
Words:117
Previous Article:MICHIGAN HIGHWAY PROGRAM SLOWING TO A HALT
Next Article:U.S. HOUSE FAILS TO OVERRIDE VETO ON GAG RULE; LOCAL FAMILY PLANNING AGENCIES SAY THE FIGHT GOES ON
Topics:


Related Articles
INSTITUTE FOR LABORATORY MEDICINE SELLS FLORIDA LABORATORY ASSURING COMPLIANCE WITH STARK AMENDMENT
INSTITUTE FOR LABORATORY MEDICINE SELLS FLORIDA LABORATORY ASSURING COMPLIANCE WITH STARK AMENDMENT
ENDOTRONICS, INC. REPORTS RESULTS FOR FIRST QUARTER ENDED DEC. 31, 1991
GENETICS INSTITUTE REPORTS FIRST QUARTER 1993 FINANCIAL RESULTS
GENETICS INSTITUTE REPORTS SECOND QUARTER 1995 FINANCIAL RESULTS
National Genetics Institute's SUPERQUANT(TM) HCV Assay is the First Test to Demonstrate the Antiviral Effects of a FDA Approved Treatment for Chronic...
Myriad Genetics, Inc. Reports Results for First Quarter of Fiscal 2002.
IDEXX REPORTS 3RD QTR NET INCOME INCREASED 22%.
The Rothberg Institute for Childhood Diseases Launches First International Effort to Fight Malaria; Computational efforts focused on making medicines...
Transgenomic, Inc. Reports First Quarter 2008 Results.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters